Roche Holding AG (LON:0QOK)
London · Delayed Price · Currency is GBP · Price in CHF | Market Cap | 242.64B +15.0% |
| Revenue (ttm) | 59.37B +1.5% |
| Net Income | 12.07B +55.6% |
| EPS | 15.03 +55.6% |
| Shares Out | n/a |
| PE Ratio | 20.11 |
| Forward PE | 15.67 |
| Dividend | 9.36 (2.92%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 409,555 |
| Average Volume | 1,589,321 |
| Open | 320.70 |
| Previous Close | 320.21 |
| Day's Range | 316.60 - 325.00 |
| 52-Week Range | 221.30 - 377.00 |
| Beta | 0.21 |
| RSI | 28.00 |
| Earnings Date | Apr 24, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
Harbor Health Care ETF Q4 2025 Portfolio Review
Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly deliv...
Roche Annual General Meeting 2026
Basel, 10 March 2026 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting. The 594 shareholders in ...
Glooko to Expand EMEA CGM Connectivity with Roche Accu-Chek® SmartGuide Integration
GOTHENBURG, Sweden--(BUSINESS WIRE)--Glooko, Inc., a globally integrated digital healthcare company focused on helping healthcare systems solve the growing challenges of glycemic safety and diabetes m...
Strait of Hormuz will partially reopen in 2-3 weeks: David Roche
Quantum Strategy' David Roche says he expects oil reserves can sufficiently support world demand, and that the 'world won't run out of oil'. He also explains why he believes Iran can't afford to escal...
Roche Holding AG (RHHBY) Discusses Phase III Study Results and Updates on Immunology Kidney Pipeline Transcript
Roche Holding AG (RHHBY) Discusses Phase III Study Results and Updates on Immunology Kidney Pipeline Transcript
Roche shares drop as oral breast cancer drug fails in trial
Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its promising drug candidate giredestrant against a common form of breast cancer can help newly diagnosed pa...
Roche Breast-Cancer Treatment Falls Short of Primary Goal in Late-Stage Study
The combination of Roche's investigational drug, giredestrant, with Pfizer's Ibrance didn't lead to a statistically significant improvement among patients with advanced breast cancer.
Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from the Phase III persevERA Breast Cancer study evaluating i...
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
Basel, 9 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the phase III persevERA Breast Cancer study evaluating investigational giredestrant in combination with palbocicli...
Roche chairman still expects diagnostics hit from US tariffs
Roche expects its agreement with the U.S. government will keep its medicines exempt from the current round of import tariffs, but its diagnostics division remains exposed and could face renewed duti...
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche's Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Basel, 06 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of the phase III ALLEGORY trial of Gazyva®/Gazyvaro® (obinutuzumab) in adults with systemic lupus ery...
New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech's Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the Phase III ALLEGORY trial of Gazyva® (...
Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
The company said the data supported further development of the drug in chronic weight management on its own or in combination with other drugs due to its tolerability.
Roche's obesity drug shows up to 10.7% weight loss in mid-stage trial
Genentech, part of Roche , said on Thursday that its experimental obesity drug helped people lose up to 10.7% of their body weight in a mid-stage study.
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
Basel, 05 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from the Phase II ZUPREME-1 trial evaluating investigational petrelintide versus placebo in 493 peopl...
Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase II ZUPREME-1 trial evaluating...
New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools
Global survey of 4,326 people with diabetes shows how the unpredictability and mental burden associated with managing the condition negatively impacts daily life.1 Majority of respondents say that con...
Roche targets double-digit market share in weight loss, aims to catch up with Novo Nordisk, Handelsblatt reports
Swiss pharmaceutical company Roche is aiming for a double-digit market share in the weight loss market and wants to close the gap on its Danish rival Novo Nordisk , its CEO told Germany's Hand...
Roche Multiple Sclerosis Drug Meets Key Goal in Late-Stage Trial
The drugmaker said the results provide convincing evidence that fenebrutinib can become the first high-efficacy oral treatment for relapsing and primary progressive multiple sclerosis.
Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS ...
[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)
Basel, 02 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically meaningful a...
Quantum Strategy's David Roche thinks Iran regime could be 'gone within a year'
David Roche of Quantum Strategy explains why he believes Iran's current regime could fall within a year. He also says he does not see Tehran conceding to U.S. demands to limit its nuclear program, vie...
FDA Approves Genentech's Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the com...
FDA Accepts New Drug Application for Genentech's Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com...
FDA accepts New Drug Application for Roche's giredestrant in ESR1-mutated, ER-positive advanced breast cancer
Basel, 20 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States (U.S.) Food and Drug Administration (FDA) has accepted the company's New Drug Application for girede...